Emerging Considerations in the Use of Immune Checkpoint Inhibitors: What is MSI?
Drs Overman and Sinicrope discuss the emergence of MSI-H: what it is, how it may be used to help guide treatment with immunotherapy.
The goal of this activity is to discuss the evolving role of MSI to help guide cancer immunotherapies.
This activity is intended for oncologists, gastroenterologists, and pathologists
Approximate Time to Complete: 30 minutes
Credit Available: Nov. 28, 2017 - Nov. 28, 2018
Developed through a partnership between SITC and Medscape.
 |
 |
- Have increased knowledge regarding the definition of microsatellite instability (MSI) in patients with cancer
- Have increased knowledge regarding the clinical data on the potential utility of MSI as a biomarker in patients being considered for treatment with immune checkpoint inhibitors
AMA PRA Category 1 Credit(s)™: 0.50
ABIM MOC Part 2 Credits: 0.50
Contact Hour: 0.50